Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Thrombocytopenia 1Neutropenia 1Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Breast Neoplasms 1Anemia 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Moxibustion × Gastrointestinal × Clear all
NCT02781155 2016-05-24

Limiting Chemotherapy Side Effects by Using Moxa

East and North Hertfordshire NHS Trust

Phase 1/2 Unknown
25 enrolled
BreastClassical hematologyGastrointestinal

Anemia, Breast Neoplasms, Genital Neoplasms, Female, Neoplasms, Neutropenia, Thrombocytopenia, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡